Wegovy Symptoms: What Most People Experience and What to Watch For

Step 1: What happens in the first days after your initial dose

Wegovy's starting dose is 0.25 mg, and its primary job at that level is to let your system settle in. Most people notice something in the gut, a slight queasiness after eating, feeling full faster than expected, or looser stools. These effects are a direct consequence of semaglutide slowing gastric emptying: food moves through the stomach more slowly, which is part of how the medicine reduces appetite, but which also explains why the digestive system takes time to recalibrate.

Fatigue and headache show up for some people in week one. These are not signs of infection; they are more likely linked to reduced calorie intake and the body adjusting to a different eating rhythm. People who start treatment mid-week sometimes notice these most sharply on the second or third day, worth bearing in mind if you are timing your first dose around a busy stretch at work.

The day-one semaglutide symptoms page goes into more detail on what the first 24–48 hours look like for most people. The NHS's patient information on semaglutide side effects also sets out which effects are common and which are rare, using standard frequency bands from clinical data.

Step 2: The pattern across dose increases, including flu-like symptoms on Wegovy

Wegovy is titrated gradually: 0.25 mg for a month, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg as the maintenance dose, each step guided by your prescriber. A common pattern is that symptoms that had quietened down at one dose return briefly when the dose goes up. That temporary flare is normal and usually short-lived.

Flu-like symptoms on Wegovy (fatigue, mild aching, chills, headache) can reappear at this point. They are reported often enough that they appear in the prescribing information, but they are not caused by a virus. The mechanism is similar to dose-start effects: the body responding to a higher level of GLP-1 receptor activity. Most people find these resolve within a week of each increase.

If you want a fuller picture of what to expect across the course of treatment, the symptoms of taking Wegovy page covers the range of effects that people commonly report at each stage of the titration schedule. Staying well-hydrated, eating smaller meals slowly, and avoiding high-fat food in the first weeks are the practical steps most clinicians recommend during titration. Specific advice on managing your regimen belongs with your prescriber or in the Patient Information Leaflet, not a content page, but those habits are broadly consistent across the clinical literature.

If you are considering whether Wegovy is the right option for you, the benefits of semaglutide page gives a grounded summary of what the trial evidence actually shows.

Step 3: Less common symptoms and the ones that require urgent help

Beyond the GI cluster, a smaller proportion of people on Wegovy report injection-site reactions (redness, itching, a small lump that fades), mild dizziness, and in some cases low mood or changes in energy. These are documented in the licensed prescribing information and the NHS medicines guidance.

Wegovy can also cause flu-like symptoms that are genuinely easy to mistake for a seasonal illness: aching limbs, a general sense of feeling unwell, or low-grade temperature. The practical distinction is that true flu tends to come with a fever and respiratory symptoms; Wegovy-related fatigue and malaise typically do not. If you are unsure, your GP or pharmacist can help you tell the difference.

There are symptoms that should not be waited out. Severe stomach pain that radiates to the back, with or without vomiting, can be a sign of acute pancreatitis, a known but infrequent risk with GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update in January 2026: anyone on a GLP-1 medicine who develops this kind of pain should seek urgent medical attention. Separately, signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) also need emergency care. Signs of gallbladder problems (pain in the upper right abdomen, fever, jaundice) are another category to escalate promptly.

You can report a suspected side effect directly to the MHRA through the Yellow Card scheme, which is open to patients as well as healthcare professionals. It is one of the clearest signals the regulator uses to track emerging safety patterns in newly approved medicines.

Step 4: Symptoms that appear if you stop Wegovy

A question that comes up less often is what happens on the other side of treatment. Stopping Wegovy is not associated with acute withdrawal in the way some medicines are, but appetite tends to return (sometimes noticeably) as the GLP-1 effect fades. Some people describe a rebound in hunger within days of their last dose. This is not a symptom of the medicine so much as the underlying condition reasserting itself without pharmacological support.

The symptoms of stopping Wegovy page covers this in more detail for people weighing up what a break or an end to treatment would mean in practice. Any decision about stopping should go through your prescriber rather than being made unilaterally, particularly for people who have been on Wegovy for several months at maintenance dose.

For context on how Wegovy is obtained through a regulated private route, the Wegovy overview page at nume explains the clinical process, eligibility outline and what the service includes. If you are ready to find out whether treatment is right for you, you can check your eligibility with our clinical team.